info@oncologyventure.com

2X Oncology to Present at Jefferies Global Healthcare Conference

 

Cambridge, MA — May 31, 2017 — 2X Oncology, Inc. (“2X” or the “Company”), a company focused on developing targeted therapeutics to address significant unmet needs in women’s cancer, today announced that its chief executive officer, George O. Elston, will present at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 10:00 am EDT.

The 2X presentation will be webcast live and archived for 90 days on the Company’s website under the ‘News’ tab.

Mr. Elston will be joined by other members of the executive team for a breakout session immediately after the presentation, and for one-on-one meetings throughout the conference.  Please contact your Jefferies representative or Amy Raskopf to schedule a meeting with 2X.

About 2X Oncology

2X Oncology Inc. is a is a clinical stage company developing targeted therapeutics that leverage proprietary Drug Response Predictor (DRP™) companion diagnostic technology to address significant unmet needs in women’s cancer.  The DRP generates a precision mRNA-based companion diagnostic for each compound, enabling the identification of patients that are most likely to respond and benefit from treatment.

The 2X pipeline includes product candidates focused on breast, ovarian, and endometrial cancers and primary and secondary brain tumors.  These programs have shown clinical efficacy and safety and are positioned to enter focused Phase 2 studies with data expected in 2018.

A Cambridge, MA based spin-out from Oncology Venture ApS, 2X works in close collaboration with Oncology Venture and leverages its Danish registry of over 1,100 cancer patients for initial clinical studies. Learn more at 2xoncology.com.

DRP™ is a trademark of Medical Prognosis Institute A/S.